Association of Mycoplasma pneumoniae antibody titer level with clinical severity of pneumonia in children

Fatmah Bibi Rajah; Rongxiu Zheng; Yuhui Zhou; Kan Xuan

doi:10.24294/jpedd.v1i0.105

Association of Mycoplasma pneumoniae antibody titer level with clinical severity of pneumonia in children

Fatmah Bibi Rajah, Rongxiu Zheng, Yuhui Zhou, Kan Xuan

Article ID: 105
Vol 3, Issue 1, 2020

VIEWS - 670 (Abstract)

Abstract

The objectives is to establish a positive correlation between the serology titer of Mycoplasma pneumoniae and the severity of pneumonia, with an emphasis on severity of disease presentation between two different age groups. The research included 110 children admitted at the Tianjin Medical University General Hospital, Tianjin, China, from May 2010 to October 2010. This study included disease history, clinical examination findings, laboratory investigations including Mycoplasma pneumoniae antibody titer (MP-IgM) level as well as imaging, and duration of in-patient treatment. The results of the parameters were also compared between two age groups: children <5 years old and ≥5 years old. Seventy-six percent of the patients who had severe presentation of the disease had a high titer of MP-IgM and 63% of them were older than five years. Platelet level seems to be a promising indicator of progression of disease. Leukocytosis was present in only 4.5% of the 110 children. The C-reactive protein was significantly raised in those older than five years of age. A significant correlation has been found between the severity of disease and Mycoplasma pneumoniae serology titer level in children suffering from Mycoplasma pneumoniae pneumonia.

Keywords

Mycoplasma pneumoniae; MP-IgM; pneumonia in children; thrombocytosis

Full Text:

PDF

References

1. Waites KB, Talkington DE. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17(4), 697–728. doi: 10.1128/CMR.17.4.697-728.2004

2. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113(4): 701–707. doi: 10.1542/peds.113.4.701

3. Principi N, Esposito S, Blasi F. Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumonia in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001; 32(9): 1281–1289. doi: 10.1086/319981

4. Othman N, Isaacs D, Kesson A. Mycoplasma pneumoniae infections in Australian children. J Paediatr Child Health 2005; 41(12): 671–676. doi: 10.1111/j.1440-1754.2005.00757.x

5. Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Resp Med 2008; 102(12): 1762–1728. doi: 10.1016/j.rmed.2008.06.022

6. Bunnag T, Lochindarat S, Srisan P, Jetanachai P. Mycoplasma pneumonia in young children, 2–5 years of age. J Med Assoc Thai 2008; 91(Suppl 3): S124–S127.

7. Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, et al. Incidence of upper respiratory tract Mycoplasma pneumoniae infections among outpatients in Rhône-Alpes, France, during five successive winter periods. J Clin Microbiol 1999; 37(6): 1721–1726.

8. Jacobs E. Mycoplasma pneumoniae. Disease manifestations and epidemiology. In: Razin S and Herrman R (eds). Molecular biology and pathogenicity of mycoplasmas. New York, NY, USA: Kluwer Academic/Plenum Publishers; 2002. p. 519–530. doi: 10.1007/0-306-47606-1_23

9. Nilsson AC, Björkman P, Welinder-Olsson C, Widell A, Persson K. Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infectious Diseases 2010; 10: 39. doi:10.1186/1471-2334-10-39

10. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatrics 2010; 10: 48. doi: 10.1186/1471-2431-10-48

11. Glader B. The anemias. 18th ed. In: Behrman RE, Kliegman RM, Jenson HB, Stanton BF (eds). Nelson textbook of pediatrics. Philadelphia, PA, USA: WB Saunders Co.; 2007. p. 2003.

12. Klinger MHF, Jelkmann W. Review: Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22(9): 913–922. doi: 10.1089/10799900260286623

13. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238(1): 1–9. doi: 10.1016/j.cellimm.2005.12.005

14. von Hundelshausen P, Weber C. Platelets as immune cells: Bridging inflammation and cardiovascular disease. Circ Res 2007; 100(1): 27–40. doi: 10.1161/01.RES.0000252802.25497.b7

15. Hamano-Hasegawa K, Morozumi M, Nakayama E, Chiba N, Murayama SY, et al. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. J Infect Chemother 2008; 14(6): 424–432. doi: 10.1007/s10156-008-0648-6

16. Beersma MFC, Dirven K, van Dam AP, Templeton KE, Claas ECJ, et al. Evaluation of 12 commercial tests and the complementary fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”. J Clin Microbiol 2005; 43(5): 2277–2285. doi: 10.1128/JCM.43.5.2277-2285.2005

17. Ozaki T, Nishimura N, Ahn J, Watanabe N, Muto T, et al. Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates. J Infect Chemother 2007; 13(4): 204–207. doi: 10.1007/s10156-007-0519-6

DOI: https://doi.org/10.24294/jpedd.v1i0.105